Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas

Silvana Novelli, Anna Monter, M. Pilar García-Muret, Rodrigo Martino, Javier Briones, Jorge Sierra

Research output: Contribution to journalReview articleResearchpeer-review

1 Citation (Scopus)

Abstract

© 2019, Japanese Society of Hematology. Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.
Original languageEnglish
Pages (from-to)406-410
JournalInternational Journal of Hematology
Volume110
Issue number4
DOIs
Publication statusPublished - 1 Oct 2019

Keywords

  • Allogeneic hematopoietic transplantation
  • Cutaneous T cell lymphoma
  • Mycosis fungoide
  • Sézary syndrome

Fingerprint

Dive into the research topics of 'Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas'. Together they form a unique fingerprint.

Cite this